Výsledky vyhledávání

Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD

Autor: Axel Facius, Henrik Watz, Jonas Román, Stephen I. Rennard, Nitin Bagul, Klaus F. Rabe, Peter M.A. Calverley, Vijay Kt Alagappan

Publikováno v: International Journal of Chronic Obstructive Pulmonary Disease
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Henrik Watz,1 Nitin Bagul,2 Klaus F Rabe,3,4 Stephen Rennard,5,6 Vijay KT Alagappan,7 Jonas Román,8 Axel Facius,9 Peter MA Calverley10 1Pulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::200633d526b18aebc27d4cf34ee60a5b
http://europepmc.org/articles/PMC5846760

Zobrazit plný text záznamu

Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials

Autor: Leonardo M. Fabbri, Vijay Alagappan, Antonio Anzueto, Peter M.A. Calverley, Jonas Román, Andrew McIvor, Shahid Siddiqui, Sofia Zetterstrand, Emilio Pizzichini, Debasree Purkayastha, Klaus F. Rabe, Nitin Bagul, Sanjay Sethi, Colin Reisner, Fernando J. Martinez, Stephen I. Rennard

Publikováno v: American journal of respiratory and critical care medicine. 198(10)

Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of exacerbations. Further characterization of patients most likely to benefit is warranted.Define charact

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b50f8c9a30f9bc43a936ac56992bacfb
https://pubmed.ncbi.nlm.nih.gov/29953246

Zobrazit plný text záznamu

Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial

Autor: Frauke Pedersen, Nitin Bagul, Vijay Alagappan, Klaus F. Rabe, Marina Saetta, Guido Hanauer, Jonas Román, Debasree Purkayastha, Simonetta Baraldo, Udo-Michael Göhring, Davide Biondini, Henrik Watz

Summary Background The clinical effects of roflumilast, a selective phosphodiesterase-4 inhibitor, are well established, but little is known about the anti-inflammatory mechanisms underlying the drug's efficacy. The aim of the ROflumilast Biopsy Euro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::850295d1f3d1134af5a07435c6196197
http://hdl.handle.net/11577/3287421

Zobrazit plný text záznamu

Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE)

Autor: Henrik Watz, Udo-Michael Goehring, Klaus F. Rabe, Peter M.A. Calverley, Ken Nip, Nitin Bagul, Rui Sun

Publikováno v: 5.1 Airway Pharmacology and Treatment.

Background: The oral phosphodiesterase 4 inhibitor roflumilast (ROF) (approved dose 500µg OD) reduces exacerbations in severe COPD. Adverse events (AE), which can occur in the first weeks of treatment, may limit its use. Methods: We performed a mult

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4f94f0925ecc948e34d74b280c18d942
https://doi.org/10.1183/13993003.congress-2016.pa308

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání